Techno Drugs (DHA:TECHNODRUG) Selling, General, & Admin. Expense: BDT55 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT44.50
! 9 Warning Signs
View Full Analysis

What is Techno Drugs Selling, General, & Admin. Expense?

Techno Drugs DHA:TECHNODRUG +3.73% 37 Selling, General, & Admin. Expense is BDT55 Mil as of Mar. 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 9 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Techno Drugs's selling, general, & admin. expense for the three months ended in Mar. 2026 was BDT131 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT55 Mil.


Techno Drugs  (DHA:TECHNODRUG) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Techno Drugs Selling, General, & Admin. Expense Related Terms


Techno Drugs Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Techno Drugs's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs Selling, General, & Admin. Expense Chart

Techno Drugs Annual Data
Trend Jun24 Jun25
Selling, General, & Admin. Expense
171.22 149.48

Techno Drugs Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 146.79 -447.52 186.86 185.02 131.04

DHA:TECHNODRUG vs ZTS, UTHR, VTRS: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Techno Drugs Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Techno Drugs's Selling, General, & Admin. Expense falls into.


DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of BDT55 Mil mean?
Techno Drugs (DHA:TECHNODRUG) has a Selling, General, & Admin. Expense of BDT55 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Techno Drugs and its competitors.
Is Techno Drugs' Selling, General, & Admin. Expense too high?
Techno Drugs' current Selling, General, & Admin. Expense is BDT55 Mil. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Selling, General, & Admin. Expense compare to ZTS and UTHR?
Techno Drugs' Selling, General, & Admin. Expense of BDT55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Techno Drugs and its competitors. Techno Drugs's current Selling, General, & Admin. Expense is BDT55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Selling, General, & Admin. Expense of BDT55 Mil. The current Selling, General, & Admin. Expense is BDT55 Mil. Techno Drugs' overall GF Score™ is 37/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Selling, General, & Admin. Expense is BDT55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT44.50
Price